A surprisingly long list of medications can push the thyroid into overdrive. Amiodarone, lithium, interferon-alpha, immune checkpoint inhibitors, tyrosine kinase inhibitors, alemtuzumab, antiretroviral therapy, iodine-based contrast agents, and even exogenous thyroid hormone itself have all been linked to drug-induced hyperthyroidism. The mechanisms vary widely, from direct toxic damage to the thyroid gland to immune system remodeling that triggers autoimmune disease months after treatment begins. Understanding which drugs carry this risk matters because drug-induced thyrotoxicosis is frequently missed or attributed to other causes, delaying treatment that can prevent serious cardiovascular complications.
Amiodarone, the Most Notorious Offender
Amiodarone, a widely prescribed antiarrhythmic drug, is probably the single medication most associated with thyroid problems. About 37 percent of its molecular weight is iodine, which means a standard daily dose delivers far more iodine than the thyroid normally encounters. This iodine overload, combined with the drug’s direct toxic effects on thyroid cells, creates two distinct pathways to hyperthyroidism. Type 1 amiodarone-induced thyrotoxicosis is essentially iodine-driven overproduction of thyroid hormone, and it tends to develop in people who already have an underlying thyroid abnormality such as a goiter or nodules. Type 2 is a destructive thyroiditis where the drug damages thyroid tissue directly, causing stored hormone to leak into the bloodstream; this form typically strikes people with apparently normal thyroid glands.1The Journal of Clinical Endocrinology & Metabolism. Approach to the Patient with Amiodarone-Induced Thyrotoxicosis Mixed forms that combine both mechanisms also exist, and they can be difficult to classify.
The practical headache with amiodarone is that it has an extraordinarily long half-life, lingering in fat tissue for months after the last dose. Thyroid problems can surface weeks or even months after stopping the drug, which catches both patients and clinicians off guard. Differentiating between type 1 and type 2 matters because the treatments are different: type 1 responds to antithyroid drugs, while type 2 often needs corticosteroids. Established methods like color flow Doppler ultrasound and radioiodine uptake testing help distinguish the two, but they are not perfectly accurate, and misclassification can delay effective treatment.2British Journal of Radiology. Evaluation of 99mTc-MIBI in thyroid gland imaging for the diagnosis of amiodarone-induced thyrotoxicosis
Guidelines from the American Thyroid Association recommend checking thyroid function before starting amiodarone and monitoring at regular intervals for as long as the patient takes it.3Journal of the Endocrine Society. Monitoring Thyroid Function in Patients on Amiodarone: A Review of Practice Patterns and Adherence to the Recommended Guidelines in a Health Care System A structured monitoring approach helps catch dysfunction early while preserving arrhythmia control.4PubMed. Amiodarone-associated thyroid dysfunction: Current evidence and a practical approach to management
Iodine-Containing Agents and the Jod-Basedow Phenomenon
Amiodarone is not the only iodine-related culprit. Iodinated contrast dye, used routinely in CT scans and cardiac catheterizations, delivers a massive iodine bolus that can trigger hyperthyroidism in people with preexisting nodular thyroid disease. This reaction, called the Jod-Basedow phenomenon, occurs because autonomous thyroid nodules take up the sudden iodine surplus and churn out excess hormone without the normal feedback brakes. Repeated contrast exposures can compound the risk and cause severe complications.5Journal of the Endocrine Society. MON-451 Contrast Induced Hyperthyroidism (Jod Basedow Phenomenon) in a Patient With a Thyroid Nodule
This is worth knowing if you have ever been told you have thyroid nodules or a multinodular goiter. The risk is not theoretical: a large population-based study found that people who developed iodine-induced hyperthyroidism had a roughly 20 percent higher long-term risk of atrial fibrillation and flutter compared with those who stayed euthyroid after iodine exposure.6PubMed Central. Iodine-Induced Hyperthyroidism and Long-term Risks of Incident Atrial Fibrillation and Flutter Given how frequently contrast scans are ordered, this downstream cardiac risk deserves attention, especially in older adults who are both more likely to have nodular thyroid disease and more vulnerable to heart rhythm disturbances.
Immune Checkpoint Inhibitors
Cancer immunotherapy has transformed outcomes for many tumor types, but it has also introduced an entirely new category of thyroid side effects. Checkpoint inhibitors like pembrolizumab (anti-PD-1) and ipilimumab (anti-CTLA-4) work by releasing the immune system’s brakes so it can attack cancer cells. A side effect of that unleashed immune response is that the immune system sometimes attacks the thyroid too. The most common clinical pattern is a destructive thyroiditis: the gland becomes inflamed, spills its stored hormone, and produces a temporary thyrotoxic phase that often tips over into lasting hypothyroidism.7PubMed Central. Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms
The risk climbs steeply when checkpoint inhibitors are combined. When ipilimumab and nivolumab are given together, thyroid dysfunction becomes more frequent and starts sooner. One analysis found the median time to thyrotoxicosis was about two weeks with the combination, versus roughly six weeks with nivolumab alone.8BMJ Case Reports. Thyroid storm induced by combined nivolumab and ipilimumab immunotherapy in advanced non-small cell lung cancer In rare cases, the thyroid storm triggered by combination immunotherapy can be life-threatening. Because these drugs are being used in an expanding range of cancers, oncologists and endocrinologists are seeing more of these cases every year.
Alemtuzumab and Autoimmune Thyroid Disease
Alemtuzumab, a monoclonal antibody used to treat multiple sclerosis, stands out because it does not just cause fleeting thyroiditis. It rewires the immune system in a way that frequently triggers full-blown Graves’ disease, the autoimmune condition where the body produces antibodies that stimulate the thyroid to overproduce hormone. The numbers are striking: in one cohort, about 41 percent of treated patients developed thyroid dysfunction, and the majority of those cases were Graves’ disease.9PubMed Central. Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features A Danish cohort study found a similar rate, with thyroid disease in 47 percent of patients and Graves’ disease accounting for about 35 percent.10PubMed. Alemtuzumab-induced thyroid disease: A Danish cohort study
The timing is unusual. Graves’ disease after alemtuzumab does not appear right away. The median onset in one large series was 17 months after the last dose, with most cases emerging within three years but some appearing as late as nine years out.9PubMed Central. Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features This delay means that monitoring has to continue long after the treatment course ends. Among patients who developed alemtuzumab-induced Graves’ disease in that series, about two-thirds eventually needed definitive treatment such as radioiodine, surgery, or long-term antithyroid drugs, suggesting the disease is not a self-limiting nuisance but a persistent condition requiring ongoing management.
Lithium
Lithium is best known for causing hypothyroidism, but it can also trigger hyperthyroidism, typically through silent thyroiditis. In silent thyroiditis, the gland becomes inflamed without pain, leaks stored thyroid hormone, and causes a thyrotoxic phase before eventually burning out. One study found that people taking lithium had nearly five times the odds of developing silent thyroiditis compared with patients who had Graves’ disease, and the incidence of lithium-associated thyrotoxicosis was roughly two to three times higher than the background rate in the general population.11PubMed. Association between lithium use and thyrotoxicosis caused by silent thyroiditis Rarely, lithium has also been linked to outright Graves’ disease.12PubMed. Lithium and thyroid
A dangerous wrinkle is that if thyrotoxicosis develops in a patient already on lithium, the resulting dehydration and increased metabolic rate can push lithium levels to toxic concentrations. One reported case involved thyrotoxicosis from silent thyroiditis precipitating severe lithium toxicity that led to cardiac arrest and quadriplegia.13PubMed. Lithium toxicity precipitated by thyrotoxicosis due to silent thyroiditis: cardiac arrest, quadriplegia, and coma For people on long-term lithium, periodic thyroid function checks are standard practice, and any new symptoms like unexpected weight loss, tremor, or a racing heartbeat should prompt testing.
Interferon-Alpha
Interferon-alpha, once a mainstay for treating hepatitis C and still used in some oncology settings, is a potent trigger of thyroid inflammation. Up to 40 percent of hepatitis C patients treated with interferon-alpha develop some form of clinical or subclinical thyroid disease.14PubMed Central. Interferon induced thyroiditis The thyroid effects can look like classic autoimmune disease, presenting as either Hashimoto’s thyroiditis or Graves’ disease, or they can take the form of a non-autoimmune destructive thyroiditis that produces early thyrotoxicosis followed by hypothyroidism.
In one long-term follow-up study of hepatitis C patients, about 4 percent developed symptomatic autoimmune thyroid disease during interferon therapy, split roughly evenly between hyperthyroidism and hypothyroidism.15PubMed. Long-term outcome of interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C Some patients who developed Graves’-like hyperthyroidism needed antithyroid treatment for months.16Archives of Internal Medicine. Increased Risk of Autoimmune Thyroid Disease in Hepatitis C vs Hepatitis B Before, During, and After Discontinuing Interferon Therapy Although direct-acting antivirals have largely replaced interferon for hepatitis C, interferon-alpha remains relevant in certain hematologic cancers, and its thyroid effects serve as a useful reminder that cytokine-based therapies carry inherent immune risks.
Tyrosine Kinase Inhibitors
Targeted cancer drugs like sunitinib, sorafenib, and other tyrosine kinase inhibitors have become workhorses in the treatment of renal cell carcinoma, hepatocellular carcinoma, and other cancers. These drugs affect the thyroid through several proposed mechanisms: they can trigger destructive thyroiditis, cause blood vessel regression within the gland, stimulate production of antithyroid antibodies, and impair iodine uptake.17PubMed Central. Tyrosine kinase inhibitors induced thyroid dysfunction: a review of its incidence, pathophysiology, clinical relevance, and treatment
The clinical pattern with sunitinib is particularly interesting because it cycles with the drug schedule. Sunitinib is typically given in on-off cycles. Some patients develop thyrotoxicosis during the early weeks of treatment that recurs with each cycle, with two patterns: an early, severe form appearing within the first ten weeks, and a later, milder form that progresses quickly to hypothyroidism.18PubMed. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma The late-onset version is essentially a slow dismantling of the gland, with each cycle causing another wave of damage until the thyroid can no longer function. Thyroid monitoring is now a standard part of care for patients on tyrosine kinase inhibitors.
Antiretroviral Therapy and Immune Reconstitution
HIV treatment with highly active antiretroviral therapy occasionally triggers Graves’ disease as part of immune reconstitution inflammatory syndrome. When the immune system rebuilds itself after being suppressed by HIV, newly generated immune cells sometimes target the thyroid. This is thought to involve the thymus, which produces new T cells during immune recovery; if the regenerating thymus fails to properly filter out self-reactive clones, autoimmune thyroid disease can result.19PubMed. Graves’ disease during immune reconstitution after highly active antiretroviral therapy for HIV infection: evidence of thymic dysfunction
The timeline is delayed compared with most drug reactions. In one reported case, a patient whose CD4 count had risen dramatically after starting antiretrovirals developed severe Graves’ disease nearly three years into treatment.19PubMed. Graves’ disease during immune reconstitution after highly active antiretroviral therapy for HIV infection: evidence of thymic dysfunction Pediatric cases have also been documented, though they remain exceptionally rare.20IDCases. Grave’s disease as a manifestation of immune reconstitution inflammatory syndrome in an HIV-infected child on highly active antiretroviral therapy: A case report This particular form of drug-induced hyperthyroidism is a paradox of successful treatment: the better the immune recovery, the higher the theoretical risk that the reconstituted immune system will make mistakes.
Exogenous Thyroid Hormone Misuse
Not every case of drug-induced hyperthyroidism involves an unintended side effect. Factitious thyrotoxicosis occurs when someone deliberately or accidentally ingests more thyroid hormone than prescribed. This includes people who take excessive levothyroxine (T4), liothyronine (T3), or thyroid extracts, sometimes for weight loss or bodybuilding purposes.21PubMed. Factitious thyrotoxicosis and thyroid hormone misuse or abuse In one reported case, an athlete abusing thyroxine for bodybuilding presented with cardiac arrest.22PubMed Central. Thyrotoxicosis factitia: a rare cause of junctional rhythm and cardiac arrest
Factitious thyrotoxicosis is diagnostically tricky because the patient’s thyroid gland itself is normal and suppressed. The giveaway on lab work is very low thyroglobulin levels combined with elevated thyroid hormone, since the body’s own thyroid has shut down production in response to the external supply. It can be a common form of thyroid hormone abuse, and clinicians should consider it when the clinical picture does not match the usual causes of overactive thyroid, especially when patients are evasive about supplement or medication use.
Over-the-Counter Supplements and Weight Loss Products
A recurring concern is whether nonprescription weight loss supplements contain enough thyroid hormone to cause problems. Despite occasional alarming reports, a study that tested ten commercially available U.S. weight loss products found that none contained detectable amounts of T4 or T3 above the limits of detection, and none contained thyroid hormone concentrations expected to cause thyrotoxicosis or affect thyroid function testing.23PubMed Central. Negligible Thyroid Hormone Content Present in Nonprescription U.S. Weight Loss Products That said, the supplement market is vast and poorly regulated, and this study looked at only a small sample. Desiccated thyroid gland preparations, which are available in some dietary supplements, remain a potential source of exogenous thyroid hormone in products not tested by this particular analysis.
When Drug-Induced Hyperthyroidism Happens During Pregnancy
Pregnancy adds a layer of complexity because both the disease and the treatment carry risks for the fetus. All antithyroid drugs cross the placenta and can suppress the fetal thyroid, but the drugs are not equal in this regard. Propylthiouracil binds more tightly to blood proteins and is more water-soluble, which limits how much reaches the fetus compared with methimazole, making it the preferred choice during pregnancy.24PubMed Central. Management of Hyperthyroidism during Pregnancy: A Systematic Literature Review Other substances also cross freely: iodides, beta-blockers, and thyroid-stimulating antibodies all reach the fetal circulation.25PubMed. Drug therapy for hyperthyroidism in pregnancy: safety issues for mother and fetus
By about 20 weeks of gestation, the fetal thyroid is fully responsive both to stimulating antibodies from the mother and to antithyroid drugs she is taking.25PubMed. Drug therapy for hyperthyroidism in pregnancy: safety issues for mother and fetus This creates a balancing act: undertreating the mother’s hyperthyroidism exposes the fetus to excess thyroid hormone, while overtreating it with antithyroid medication can push the fetal thyroid into underactivity. If a pregnant woman is on a medication known to induce hyperthyroidism, close coordination between an endocrinologist and an obstetrician becomes essential.26Journal of Clinical & Translational Endocrinology. Hyperthyroidism in the pregnant woman: Maternal and fetal aspects
How Drug-Induced Hyperthyroidism Differs From Spontaneous Disease
One reason drug-induced hyperthyroidism is easy to miss is that the symptoms are identical to the spontaneous version: rapid heartbeat, weight loss, heat intolerance, anxiety, tremor, and sometimes protruding eyes in Graves’ cases. What sets drug-induced disease apart is the context and the timing. A patient who was perfectly euthyroid before starting amiodarone, sunitinib, or checkpoint immunotherapy and then develops thyrotoxicosis weeks to months later has a clear suspect.
The mechanism matters for management. Destructive thyroiditis, such as the type caused by checkpoint inhibitors or sunitinib, often resolves on its own or transitions to hypothyroidism that needs replacement hormone. Beta-blockers to control the heart rate and symptoms are usually sufficient while the thyrotoxic phase burns through. By contrast, drug-induced Graves’ disease, as seen with alemtuzumab, behaves like the spontaneous autoimmune version and typically requires antithyroid drugs, radioiodine, or surgery. A rapid reduction in thyroid hormone may sometimes call for combination treatment using iodine-containing compounds, lithium carbonate, perchlorate, or glucocorticoids alongside standard antithyroid drugs.27PubMed Central. Nonthionamide Drugs for the Treatment of Hyperthyroidism: From Present to Future
Medications That Distort Thyroid Lab Results Without Causing True Hyperthyroidism
It is worth mentioning that some drugs make the lab numbers look like hyperthyroidism even when the thyroid itself is fine. Medications that compete for the proteins that carry thyroid hormone through the blood can displace T4 and T3, temporarily raising free hormone levels in the test tube without causing any actual clinical disease. Heparin, certain anti-seizure medications, and high-dose salicylates are common offenders. Current lab assays that involve sample dilution tend to underestimate the effect of these circulating competitors, which means the results can be misleading in both directions. Before diagnosing drug-induced hyperthyroidism, clinicians typically need to rule out these assay artifacts, especially in hospitalized patients on multiple medications, where spurious lab values are common enough to be a genuine diagnostic trap.